drugset / Trial / NCT04688008

Relative Bioavailability of Early Phase and Late Phase Hetrombopag Olamine Formulations

NCT04688008

Phase 1 Completed 58 enrolled Jiangsu HengRui Medicine Co., Ltd.
RandomizedCrossoverOpen-labelTreatment

Summary

The primary objective of the study is to evaluate the relative bioavailability of early phase and late phase hetrombopag olamine formulations in healthy Chinese adult subjects under fasting conditions. The secondary objective of the study is to evaluate the safety of hetrombopag olamine in healthy Chinese adult subjects.

Timeline

Start
2020-09-18
Primary completion
2020-10-12
Completion
2020-10-30

Drugs

EvaluationDrugModalityDoseRoute
Subject Hetrombopag Small molecule 5 mg Oral

Indications

No indication recorded.